drugset
drugset / Trial / NCT06847399

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

NCT06847399 ↗

Phase 2 Recruiting 105 enrolled Johns Hopkins University Eli Lilly and Company · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.

Timeline

Start
2025-09-17
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lisdexamfetamine Dimesylate Small molecule — —
Subject Tirzepatide Peptide — —

Indications

binge eating disorder obesity disorder